Zealand Pharma — April 2023
-
223..
-
Nordea: We reinstate our rating on Zealand Pharma at Buy and set a DCF-derived target price of DKK 275 following the capital raise on 30 March where the company raised gross proceeds of approximately DKK 1.5bn. Our new target price of DKK 275 per share reflects the company's increased cash position and the higher number of shares outstanding.
-
Som shorter (det er jeg ikke) så er den da også ALT for risikabel at shorte med den udmelding fra Bloomberg….ud fra et risiko synspunkt. Men hvordan shortere beregner sådan en case, aner jeg jo intet om
-
Det ville jeg ihvertfald gøre HVIS jeg var short
Men lad os se hvad der sker når volumen falder lidt efter tossetimen Skulle den falde lidt tilbage, så supplerer jeg ihvertfald yderligere. -
Tænker den melding fra Blomberg v
il holde hånden under kursen fremadrettet, og gøre det sværere for shorterne at lave deres “numre” -
276K handlet på 60 min...godt tegn - stiger under høj volume
-
Hvor mange aktier er shortet p.t.?
-
Aps invest..Du finder tallene i chathistorikken for nogle dage siden.
-
Tak, omkring 3,73% for en uge siden. Dvs omkring 2,2 mill aktier der skal købes tilbage?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind